Division of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, 135 Nan-Hsiao Street, Changhua City, 500, Taiwan.
Department of Healthcare Administration, Asia University, 500 Liufeng Rd., Wufeng, Taichung City, 41354, Taiwan.
Sci Rep. 2021 Jan 13;11(1):1176. doi: 10.1038/s41598-021-81024-x.
The benefits of self-monitoring of blood glucose (SMBG) on glycemic control among type 2 diabetes (T2DM) patients not receiving insulin remains controversial. This study aimed to examine the association between SMBG and glycemic control in these patients. This retrospective longitudinal study enrolled 4987 eligible patients from a medical center in Taiwan. Data were collected from electronic medical records at 0 (baseline), 3, 6, 9, and 12 (end-point) months after enrollment. Patients were assigned to the early SMBG group or to the non-user group depending on whether they performed SMBG at baseline. Differences in glycated hemoglobin (HbA1c) reduction between groups at each time-point were assessed using SMBG group-by-time interaction in generalized estimating equations models, which were established using backward elimination method for multivariate regression analysis. Subgroup analyses for patients using non-insulin and insulin secretagogues were performed additionally. The estimated maximal difference in HbA1c reduction between groups (early SMBG users vs. non-users) was 0.55% at 3 months. Subgroup analyses showed maximal differences of 0.61% and 0.52% at 3 months in the non-insulin and insulin secretagogues groups, respectively. SMBG group-by-time interaction was statistically significant at 3 months and lasted for 12 months. The finding suggests that performing SMBG at disease onset was positively associated with better glycemic control in newly diagnosed non-insulin-treated T2DM patients, regardless whether non-insulin secretagogues or insulin secretagogues were used.
自我血糖监测(SMBG)对未接受胰岛素治疗的 2 型糖尿病(T2DM)患者血糖控制的益处仍存在争议。本研究旨在探讨这些患者中 SMBG 与血糖控制之间的关系。这项回顾性纵向研究纳入了来自台湾一家医学中心的 4987 名符合条件的患者。数据来自于入组后 0(基线)、3、6、9 和 12 个月(终点)的电子病历。根据患者在基线时是否进行 SMBG,将其分为早期 SMBG 组或非使用者组。使用广义估计方程模型,采用向后消除法进行多变量回归分析,评估两组在每个时间点的糖化血红蛋白(HbA1c)降低差异。另外还对使用非胰岛素和胰岛素促分泌剂的患者进行了亚组分析。组间 HbA1c 降低最大差异(早期 SMBG 使用者与非使用者)估计为 3 个月时 0.55%。亚组分析显示,在非胰岛素和胰岛素促分泌剂组中,3 个月时最大差异分别为 0.61%和 0.52%。3 个月时 SMBG 组与时间的交互作用具有统计学意义,并持续 12 个月。结果表明,在新诊断的未接受胰岛素治疗的 T2DM 患者中,疾病发病时进行 SMBG 与更好的血糖控制呈正相关,无论是否使用非胰岛素促分泌剂或胰岛素促分泌剂。